Suchergebnisse - "Rahman, Omar"

PubPharm (8)

1

Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors : a systematic review and meta-analysis

enthalten in: Expert review of anticancer therapy | 2017

von Lasheen, S. | Shohdy, K. | Kassem, L. | +1

2

S-1-based regimens and the risk of oral and gastrointestinal mucosal injury : a meta-analysis with comparison to other fluoropyrimidines

enthalten in: Expert opinion on drug safety | 2016

von Abdel-Rahman, O. | ElHalawani, H. | Essam-Eldin, S.

3

Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab : a systematic review and meta-analysis

enthalten in: Expert opinion on drug safety | 2015

von Abdel-Rahman, O. | ElHalawani, H.

4

Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib : a systematic review and meta-analysis

enthalten in: Expert review of anticancer therapy | 2015

von Abdel-Rahman, O. | Fouad, M.

5

Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib : a critical review and meta analysis

enthalten in: Expert review of anticancer therapy | 2015

von Abdel-Rahman, O. | Fouad, M.

6

Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors : a comparative systematic review and meta-analysis

enthalten in: Expert review of gastroenterology & hepatology | 2015

von Abdel-Rahman, O. | ElHalawani, H. | Ahmed, H. | +1

7

Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus : a comparative systematic review and meta-analysis

enthalten in: Expert review of anticancer therapy | 2015

von Abdel-Rahman, O. | Fouad, M.

8

Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis

enthalten in: Expert review of anticancer therapy | 2014

von Abdel-Rahman, O. | Fouad, M.

1
[1]